Efficacy of topical gabapentin in women with primary macular amyloidosis: A side‐by‐side triple‐blinded randomized clinical trial
Journal of Cosmetic Dermatology · 2024-05 · 23 (5) · 1677-1684
DOI: 10.1111/jocd.16180 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 30.01.2024. Verfasst von Bahareh Abtahi-Naeini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Dermatology Division of Department of Pediatrics, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Gabapentin, Pruritus, Amyloidosis, Familial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Primary cutaneous macular amyloidosis (PCMA) is a chronic pruritic cutaneous disease characterized by heterogeneous extracellular deposition of amyloid protein in the skin.
Aims
This study aimed to evaluate the efficacy of topical 6% gabapentin cream for the treatment of patients with PCMA. Materials and Methods In this triple‐blind clinical trial, a total of 34 patients, who were diagnosed with PCMA, treated using two different strategies of topical gabapentin as the active group and vehicle cream as the control group.
Results
Pruritus score reduction in both groups was statistically significant compared with the baseline value ( p < 0.001). There was a significant pigmentation score reduction in intervention group compared with control group after 1 month of the study ( p < 0.001). The differences of pigmentation score changes between the groups were not significant at month 2 ( p = 0.52) and month 3 ( p = 0.22).
Conclusions
The results of this study suggest that topical gabapentin cream may be effective as a topical agent in the treatment of pruritus associated with PCMA without any significant adverse effects. It is recommended to perform similar studies with a larger sample size and longer duration in both sexes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Dermatology Division of Department of Pediatrics, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
- Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran.
- Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Pharmaceutics, Faculty of Pharmacy and Novel Drug Delivery Systems Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
ORCID-Profile: Bahareh Abtahi-Naeini, Gita Faghihi, Zabihollah Shahmoradi, Fatemeh Paknazar, Fereshte Rastegarnasab, Jaleh Varshosaz, Mojtaba Akbari, Ali Mohammad Sabzghabaee
Zitieren
APA
Abtahi-Naeini, B., Hemati, E., Faghihi, G., Shahmoradi, Z., Paknazar, F., Rastegarnasab, F., Varshosaz, J., Hadian, M., Akbari, M., & Sabzghabaee, A. M. (2024). Efficacy of topical gabapentin in women with primary macular amyloidosis: A side‐by‐side triple‐blinded randomized clinical trial. Journal of Cosmetic Dermatology, 23(5), 1677-1684. https://doi.org/10.1111/jocd.16180
Vancouver
Abtahi-Naeini B, Hemati E, Faghihi G, Shahmoradi Z, Paknazar F, Rastegarnasab F, et al. Efficacy of topical gabapentin in women with primary macular amyloidosis: A side‐by‐side triple‐blinded randomized clinical trial. Journal of Cosmetic Dermatology. 2024;23(5):1677-1684. doi:10.1111/jocd.16180
BibTeX
@article{AbtahiNaeini2024,
author = {Abtahi-Naeini, Bahareh and Hemati, Elahe and Faghihi, Gita and Shahmoradi, Zabihollah and Paknazar, Fatemeh and Rastegarnasab, Fereshte and Varshosaz, Jaleh and Hadian, Mahdi and Akbari, Mojtaba and Sabzghabaee, Ali Mohammad},
title = {Efficacy of topical gabapentin in women with primary macular amyloidosis: A side‐by‐side triple‐blinded randomized clinical trial},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
volume = {23},
number = {5},
pages = {1677--1684},
doi = {10.1111/jocd.16180}
}
EUVIMED